The Ministry of Health of the Russian Federation registered the drug Lornoxicam lyophilisate 8 mg for the preparation of a solution for intravenous and intramuscular administration manufactured by the FSUE Moscow Endocrine Plant. The registration certificate No. LP-005003, the registration date is 22.08.2018.
The drug belongs to the pharmacotherapeutic group: The non-steroidal anti-inflammatory drug (NSAID) and is the first Russian generic of the drug Xefocam (INN - Lornoxicam) in the form of a lyophilisate.
The drug is included in the list of Vital and Essential Drugs.
Indications for use of the drug are:
- Short-term treatment of mild or moderate acute pain.
- Symptomatic therapy of pain and inflammation in the presence of osteoarthritis.
- Symptomatic therapy of pain and inflammation in the presence of rheumatoid arthritis.
The drug is recommended for use from the age of 18.
The efficacy and safety profile is confirmed in comparative studies with the drug Xefocam, lyophilisate for solution for intravenous and intramuscular administration.
The project was implemented as part of the import substitution program in accordance with the industrial plan of import substitution in the pharmaceutical industry of the Russian Federation, approved by Order of the Ministry of Industry and Trade of Russia No. 656 from March 31, 2015.
Comment type is not specified in the component properties.